RESEARCH
COVID-19 Vaccine: What Do We Know About Its Efficacy and Safety in Children ?
As COVID-19 vaccination campaigns expand to younger populations, Pfizer/BioNTech’s mRNA vaccine has shown promising results in younger populations, though data in children remain limited. Early results for ages 5–11 suggest a well-tolerated response with neutralizing antibody levels comparable to those seen in adults aged 16–25. In adolescents 12–15, no meaningful differences in reactogenicity or serious adverse events were seen compared with placebo, and vaccine efficacy reached 100% against symptomatic COVID-19 after the second dose. Trial results for children under 5 are still pending. Independent assessments, including ACIP, have concluded that the benefits of mRNA vaccination outweigh expected risks such as rare myocarditis across all eligible age groups.
Already have an account? Log in
Part of an association? Click here, you may already have full access!
Unlock the Full original article
You have access to 4 more FREE articles this month.
Click below to unlock and view this original article
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
Are you affiliated with one of our partner associations?
Click here to gain complimentary access as part your association member benefits!
0 of 4 monthly FREE articles unlocked
